Turning Point Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-11-15: Study NCT05828303; Company role Lead sponsor; Phase Phase 1; Status Withdrawn.
- 2022-07-28: Study NCT05828277; Company role Lead sponsor; Phase Phase 1; Status Withdrawn.
- 2022-02-11: Study NCT04772235; Company role Collaborator; Phase Phase 1; Status Unknown.
- 2021-12-29: Study NCT05001516; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-11-15 | NCT05828303 A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors | Lead sponsor | Phase 1 | Withdrawn | Advanced Solid Tumor; Metastatic Solid Tumor | 0 | 2025-11-30 |
| 2022-07-28 | NCT05828277 A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients | Lead sponsor | Phase 1 | Withdrawn | Locally Advanced Solid Tumor; Metastatic Solid Tumor | 0 | 2025-12-31 |
| 2022-02-11 | NCT04772235 Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients | Collaborator Lead: Instituto Oncológico Dr Rosell | Phase 1 | Unknown | Nsclc | 32 | 2026-06 |
| 2021-12-29 | NCT05001516 Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | Lead sponsor | Phase 1 | Completed | Advanced Solid Tumor | 17 | 2024-01-04 |
| 2021-09-23 | NCT05071183 A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | KRAS Mutation-Related Tumors; Metastatic Solid Tumor; Advanced Solid Tumor | 9 | 2023-03-01 |
| 2021-07-28 | NCT04849273 A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC | Lead sponsor | Phase 1 | Terminated | Non Small Cell Lung Cancer; Non-Small Cell Lung Cancer; NSCLC; Advanced Solid Tumor; Metastatic Solid Tumor; ALK Gene Mutation | 11 | 2023-04-18 |
| 2020-03-12 | NCT04094610 A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Lead sponsor | Phase 1, Phase 2 | Recruiting | Locally Advanced Solid Tumors; Metastatic Solid Tumors; Lymphoma; Primary CNS Tumors | 75 | 2027-09-30 |
| 2019-12-06 | NCT04161391 Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET Gene Mutation; Metastatic Solid Tumor; Advanced Solid Tumor | 41 | 2023-05-22 |
| 2019-09-05 | NCT03993873 Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET | Lead sponsor | Phase 1 | Active not recruiting | Advanced Solid Tumor; Metastatic Solid Tumors; MET Gene Alterations | 95 | 2027-03-03 |
| 2017-03-07 | NCT03093116 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Lead sponsor | Phase 1, Phase 2 | Recruiting | Locally Advanced Solid Tumors; Metastatic Solid Tumors | 500 | 2028-02-29 |